当前位置: 首页 >> 检索结果
共有 132541 条符合本次的查询结果, 用时 8.3249156 秒

321. Climate and health: joining up the pieces, scaling up the action.

作者: The Lancet.
来源: Lancet. 2016年388卷10055期1956页

322. Whole brain radiotherapy in patients with NSCLC and brain metastases.

作者: Cécile Le Pechoux.;Frederic Dhermain.;Benjamin Besse.
来源: Lancet. 2016年388卷10055期1960-1962页

323. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

作者: Paula Mulvenna.;Matthew Nankivell.;Rachael Barton.;Corinne Faivre-Finn.;Paula Wilson.;Elaine McColl.;Barbara Moore.;Iona Brisbane.;David Ardron.;Tanya Holt.;Sally Morgan.;Caroline Lee.;Kathryn Waite.;Neil Bayman.;Cheryl Pugh.;Benjamin Sydes.;Richard Stephens.;Mahesh K Parmar.;Ruth E Langley.
来源: Lancet. 2016年388卷10055期2004-2014页
Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBRT, the prognosis of this patient group is poor. We aimed to establish whether WBRT could be omitted without a significant effect on survival or quality of life.

324. Do NOACs ENSURE safe cardioversion in atrial fibrillation?

作者: Alexandros Briasoulis.;Luis Afonso.
来源: Lancet. 2016年388卷10055期1958-1960页

325. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.

作者: Andreas Goette.;Jose L Merino.;Michael D Ezekowitz.;Dmitry Zamoryakhin.;Michael Melino.;James Jin.;Michele F Mercuri.;Michael A Grosso.;Victor Fernandez.;Naab Al-Saady.;Natalya Pelekh.;Bela Merkely.;Sergey Zenin.;Mykola Kushnir.;Jindrich Spinar.;Valeriy Batushkin.;Joris R de Groot.;Gregory Y H Lip.; .
来源: Lancet. 2016年388卷10055期1995-2003页
Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy. Few safety data about edoxaban in patients undergoing electrical cardioversion are available.

326. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.

作者: Guillaume Cayla.;Thomas Cuisset.;Johanne Silvain.;Florence Leclercq.;Stephane Manzo-Silberman.;Christophe Saint-Etienne.;Nicolas Delarche.;Anne Bellemain-Appaix.;Grégoire Range.;Rami El Mahmoud.;Didier Carrié.;Loic Belle.;Geraud Souteyrand.;Pierre Aubry.;Pierre Sabouret.;Xavier Halna du Fretay.;Farzin Beygui.;Jean-Louis Bonnet.;Benoit Lattuca.;Christophe Pouillot.;Olivier Varenne.;Ziad Boueri.;Eric Van Belle.;Patrick Henry.;Pascal Motreff.;Simon Elhadad.;Joe-Elie Salem.;Jérémie Abtan.;Hélène Rousseau.;Jean-Philippe Collet.;Eric Vicaut.;Gilles Montalescot.; .
来源: Lancet. 2016年388卷10055期2015-2022页
Elderly patients are at high risk of ischaemic and bleeding events. Platelet function monitoring offers the possibility to individualise antiplatelet therapy to improve the therapeutic risk-benefit ratio. We aimed to assess the effect of platelet function monitoring with treatment adjustment in elderly patients stented for an acute coronary syndrome.

327. Antiplatelet strategies in elderly people: still a long way to go.

作者: Dirk Sibbing.;Steffen Massberg.
来源: Lancet. 2016年388卷10055期1962-1964页

329. Rheumatoid arthritis.

作者: Josef S Smolen.;Daniel Aletaha.;Iain B McInnes.
来源: Lancet. 2016年388卷10055期2023-2038页
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor outcomes such as high disease activity, presence of autoantibodies, and early joint damage. Treatment algorithms involve measuring disease activity with composite indices, applying a treatment-to-target strategy, and use of conventional, biological, and newz non-biological disease-modifying antirheumatic drugs. After the treatment target of stringent remission (or at least low disease activity) is maintained, dose reduction should be attempted. Although the prospects for most patients are now favourable, many still do not respond to current therapies. Accordingly, new therapies are urgently required. In this Seminar, we describe current insights into genetics and aetiology, pathophysiology, epidemiology, assessment, therapeutic agents, and treatment strategies together with unmet needs of patients with rheumatoid arthritis.

330. The map is not the territory: medical records and 21st century practice.

作者: Stephen A Martin.;Christine A Sinsky.
来源: Lancet. 2016年388卷10055期2053-2056页
Documentation of care is at risk of overtaking the delivery of care in terms of time, clinician focus, and perceived importance. The medical record as currently used for documentation contributes to increased cognitive workload, strained clinician-patient relationships, and burnout. We posit that a near verbatim transcript of the clinical encounter is neither feasible nor desirable, and that attempts to produce this exact recording are harmful to patients, clinicians, and the health system. In this Viewpoint, we focus on the alternative constructions of the medical record to bring them back to their primary purpose-to aid cognition, communicate, create a succinct account of care, and support longitudinal comprehensive care-thereby to support the building of relationships and medical decision making while decreasing workload.

331. Gout.

作者: Nicola Dalbeth.;Tony R Merriman.;Lisa K Stamp.
来源: Lancet. 2016年388卷10055期2039-2052页
Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Although environmental factors contribute to hyperuricaemia, renal and gut excretion of urate is central to regulation of serum urate, and genetic factors are important. Activation of the NLRP3 inflammasome and release of interleukin 1β have key roles in initiation of acute gout flares. A "treat to target serum urate" approach is essential for effective gout management; long-term lowering of serum urate to less than 360 μmol/L leads to crystal dissolution and ultimately to suppression of flares. An allopurinol dose-escalation strategy is frequently effective for achieving treatment targets, and several new urate-lowering drugs are also available. Worldwide, rates of initiation and continuation of urate-lowering therapy are very low, and, consequently, achievement of serum urate targets is infrequent. Strategies to improve quality of gout care are needed.

332. False dichotomies in global health: the need for integrative thinking.

作者: Julio Frenk.;Octavio Gómez-Dantés.
来源: Lancet. 2017年389卷10069期667-670页

333. Preventing violent extremism: the role of doctors.

作者: John Middleton.
来源: Lancet. 2016年388卷10057期2219-2221页

334. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

作者: Jyh-Ming Liou.;Yu-Jen Fang.;Chieh-Chang Chen.;Ming-Jong Bair.;Chi-Yang Chang.;Yi-Chia Lee.;Mei-Jyh Chen.;Chien-Chuan Chen.;Cheng-Hao Tseng.;Yao-Chun Hsu.;Ji-Yuh Lee.;Tsung-Hua Yang.;Jiing-Chyuan Luo.;Chun-Chao Chang.;Chi-Yi Chen.;Po-Yueh Chen.;Chia-Tung Shun.;Wen-Feng Hsu.;Wen-Hao Hu.;Yen-Nien Chen.;Bor-Shyang Sheu.;Jaw-Town Lin.;Jeng-Yih Wu.;Emad M El-Omar.;Ming-Shiang Wu.; .
来源: Lancet. 2016年388卷10058期2355-2365页
Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori.

335. Towards effective empirical treatment for Helicobacter pylori eradication.

作者: Francis Megraud.;Javier P Gisbert.
来源: Lancet. 2016年388卷10058期2325-2326页

336. The history, geography, and sociology of slums and the health problems of people who live in slums.

作者: Alex Ezeh.;Oyinlola Oyebode.;David Satterthwaite.;Yen-Fu Chen.;Robert Ndugwa.;Jo Sartori.;Blessing Mberu.;G J Melendez-Torres.;Tilahun Haregu.;Samuel I Watson.;Waleska Caiaffa.;Anthony Capon.;Richard J Lilford.
来源: Lancet. 2017年389卷10068期547-558页
Massive slums have become major features of cities in many low-income and middle-income countries. Here, in the first in a Series of two papers, we discuss why slums are unhealthy places with especially high risks of infection and injury. We show that children are especially vulnerable, and that the combination of malnutrition and recurrent diarrhoea leads to stunted growth and longer-term effects on cognitive development. We find that the scientific literature on slum health is underdeveloped in comparison to urban health, and poverty and health. This shortcoming is important because health is affected by factors arising from the shared physical and social environment, which have effects beyond those of poverty alone. In the second paper we will consider what can be done to improve health and make recommendations for the development of slum health as a field of study.

337. Improving the health and welfare of people who live in slums.

作者: Richard J Lilford.;Oyinlola Oyebode.;David Satterthwaite.;G J Melendez-Torres.;Yen-Fu Chen.;Blessing Mberu.;Samuel I Watson.;Jo Sartori.;Robert Ndugwa.;Waleska Caiaffa.;Tilahun Haregu.;Anthony Capon.;Ruhi Saith.;Alex Ezeh.
来源: Lancet. 2017年389卷10068期559-570页
In the first paper in this Series we assessed theoretical and empirical evidence and concluded that the health of people living in slums is a function not only of poverty but of intimately shared physical and social environments. In this paper we extend the theory of so-called neighbourhood effects. Slums offer high returns on investment because beneficial effects are shared across many people in densely populated neighbourhoods. Neighbourhood effects also help explain how and why the benefits of interventions vary between slum and non-slum spaces and between slums. We build on this spatial concept of slums to argue that, in all low-income and-middle-income countries, census tracts should henceforth be designated slum or non-slum both to inform local policy and as the basis for research surveys that build on censuses. We argue that slum health should be promoted as a topic of enquiry alongside poverty and health.

338. Revising the ICD: explaining the WHO approach.

作者: Ties Boerma.;James Harrison.;Robert Jakob.;Colin Mathers.;Anneke Schmider.;Stefanie Weber.
来源: Lancet. 2016年388卷10059期2476-2477页

339. New evidence of the tuberculosis burden in Asia demands national action.

作者: Jagat Prakash Nadda.;Poonam Khetrapal Singh.
来源: Lancet. 2016年388卷10057期2217-2219页

340. Revising the ICD: stroke is a brain disease.

作者: Raad Shakir.;Steve Davis.;Bo Norrving.;Wolfgang Grisold.;William M Carroll.;Valery Feigin.;Vladimir Hachinski.
来源: Lancet. 2016年388卷10059期2475-2476页
共有 132541 条符合本次的查询结果, 用时 8.3249156 秒